4-(4-Fluorophenoxy)butan-1-amine | 873790-24-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(4-Fluorophenoxy)butan-1-amine
• CAS: 873790-24-0
• 化学式: C₁₀H₁₄FNO
• mdl: MFCD07687074
• 分子量: 183.226
• InChiKey: QSHUIHTYAZHNNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-Fluorophenoxy)butan-1-amine 、 异氰酸1-金刚烷酯 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-Adamantan-1-yl-3-[4-(4-fluorophenoxy)butyl]urea
  参考文献：
  名称：

  Orally Bioavailable Potent Soluble Epoxide Hydrolase Inhibitors

  摘要：

  A series of N,N'-disubstituted ureas having a conformationally restricted cis- or traiis-1,4-cyclohexane alpha to the urea were prepared and tested as soluble epoxide hydrolase (sEH) inhibitors. This series of compounds showed low nanomolar to picomolar activities against recombinant human sEH. Both isomers showed similar potencies, but the trans isomers were more metabolically stable in human hepatic microsomes. Furthermore, these new potent inhibitors show a greater metabolic stability in vivo than previously described sEH inhibitors. We demonstrated that trans-4-[4-(3-adamantan-1-ylureido)cyclohexyloxy]benzoic acid 13g (t-AUCB, IC50 = 1.3 +/- 0.05 nM) had excellent oral bioavailability (98%, n = 2) and blood area under the curve in dogs and was effective in vivo to treat hypotension in lipopolysaccharide challenged murine models.

  DOI：

  10.1021/jm070270t
• 作为产物：
  描述：

  2-[4-(4-fluorophenoxy)butyl]isoindole-1,3-dione 在 一水合肼 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 4-(4-Fluorophenoxy)butan-1-amine
  参考文献：
  名称：

  Orally Bioavailable Potent Soluble Epoxide Hydrolase Inhibitors

  摘要：

  A series of N,N'-disubstituted ureas having a conformationally restricted cis- or traiis-1,4-cyclohexane alpha to the urea were prepared and tested as soluble epoxide hydrolase (sEH) inhibitors. This series of compounds showed low nanomolar to picomolar activities against recombinant human sEH. Both isomers showed similar potencies, but the trans isomers were more metabolically stable in human hepatic microsomes. Furthermore, these new potent inhibitors show a greater metabolic stability in vivo than previously described sEH inhibitors. We demonstrated that trans-4-[4-(3-adamantan-1-ylureido)cyclohexyloxy]benzoic acid 13g (t-AUCB, IC50 = 1.3 +/- 0.05 nM) had excellent oral bioavailability (98%, n = 2) and blood area under the curve in dogs and was effective in vivo to treat hypotension in lipopolysaccharide challenged murine models.

  DOI：

  10.1021/jm070270t